Phase 4 N=156 Vaccinating Children After Chemotherapy
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=347 Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
Fever After Vaccination · Fever · Seizures Fever
Primary: Number of Participants With Fever Following Vaccination — 14; 10 Participants
N/A N=89 Vaccine Immune Recovery After Leukemia
Acute Lymphoblastic Leukemia, Pediatric
Primary: Incident Infection Rate in Participants During the First Year Post-acute Lymphoblastic Leukemia Therapy — 3.60 Events per person-year
Phase 4 N=297 Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (≥) 100 Milli-International Units Per Milliliter (mIU/mL) — 251 Participants
Phase 4 N=221 Fever After Simultaneous Versus Sequential Vaccination in Young Children
Fever After Vaccination · Fever · Febrile Seizure
Primary: Number of Participants With Fever Following Vaccination — 8; 10 Participants — p=0.7588
Phase 3 N=1,630 Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Meningococcal Infections
Primary: Percentages of Subjects With a Seroresponse to Measles, Mumps, Rubella and Varicella Following Concomitant Administration of MMRV Vaccine With MenACWY-CRM Vaccine — 98…
N/A N=133 Influenza Immunity in Children
Influenza
Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005
Phase 3 N=80 A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)
Hepatitis A Virus Infection
Primary: Hepatitis A Virus (HAV) Seroconversion Rate, i.e. the Percentage of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7 After Administration…
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 3 N=754 Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
Hepatitis B · Pertussis
Primary: Percentage of Participants Responding to Hepatitis B Surface Antigen (HBsAg) — 70.16; 82.01; 65.75; 83.68 Percentage of Participants
N/A N=148 Healthy, Immunized Communities Study
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Phase 4 N=1,950 Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Influenza
Primary: Percentage of Participants With Fever (Fever Rate) Following Vaccination With Fluzone Quadrivalent Vaccine — 11.31; 12.15 percentage of participants
Phase 3 N=2,907 Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Meningococcal Infections
Primary: Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age — 72; 77; 60; 56 Percentages of subjects
Phase 3 N=1,255 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population — 20.7; 22.7; 4.5; 4.8 Percentage of participants
Phase 4 N=60 Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
Influenza
Primary: Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2015-2016 Formulation of Fluzone® Quadrivalent…
Phase 4 N=60 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
Influenza
Primary: Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions Following Vaccination With the 2014-2015 Formulation of Fluzone® Quadrivalent…
Phase 3 N=1,988 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1 — 25.5; 24.6; 21.5; 22.3 Percentage of participants
Phase 3 N=649 Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants Reporting Solicited Local or Systemic Reactions Post-Dose 5 of DAPTACEL® Vaccination — 75; 70; 36; 24 Percentage of Participants
Phase 3 N=433 Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
Hepatitis A
Primary: Number of Seropositive Subjects for Anti-HAV Antibodies — 106; 94 Participants
Phase 2 N=79 Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children
Healthy Participants
Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants
Phase 4 N=292 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
Influenza
Primary: Number of Participants Who Received Influenza Vaccine. — 250 participants
Phase 4 N=276 Efficacy & Safety of Nasal Influenza Immunisation in Children
Influenza Vaccines Efficacy and Safety
Primary: Vaccine Efficacy — 4; 2; 4; 0 Participants
Phase 4 N=223 Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
Apnea · Apnea Neonatal · Prematurity
Primary: Occurrence of Apnea — 25; 12; 80; 104 Participants — p=0.0104
Phase 4 N=60 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
Influenza
Primary: Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) — 8…
Phase 4 N=185 Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (≥) 100 Milli-International Units Per Milliliter (mIU/mL) — 88; 84…
Phase 3 N=3,547 Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
Lyme Disease
Primary: Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1 — 80.8; 34.8; 80.6; 14.6 Percentage of participants
Phase 2 N=35 Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
Influenza
Primary: Occurrence of Solicited Adverse Events Among All Subjects — 0; 0; 10; 1 Participants
Phase 4 N=34 Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
Influenza
Primary: Number of Subjects Shedding Vaccine Virus of Each Subtype by PCR — 1; 6; 9; 1 participants
Phase 4 N=60 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
Influenza
Primary: Number of Participants Reporting Solicited Injection-Site or Systemic Reactions Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent, Influenza…
Phase 3 N=955 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Varicella · Measles · Mumps
Primary: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella — 97.4; 96.3; 96.7; 98.6 Percentage of Participants